Table 3.

Stratification analysis for the association between protective genotypes and neuroblastoma susceptibility.

Variables	rs110419		rs4758051		rs10840002		rs2168101		Protective genotypes
	AG/GG vs. AA		AG/AA vs. GG		AG/GG vs. AA		GT/TT vs. GG		4–5 vs. 0–3
	AOR (95% CI) a	Pa	AOR (95% CI) a	Pa	AOR (95% CI) a	Pa	AOR (95% CI) a	Pa	AOR (95% CI) a	Pa
AGE, MONTH
≤ 18	0.62 (0.42–0.93)	0.020	0.71 (0.47–1.07)	0.099	0.73 (0.48–1.12)	0.147	0.65 (0.44–0.97)	0.034	0.60 (0.40–0.90)	0.013
>18	0.63 (0.44–0.90)	0.011	0.58 (0.41–0.84)	0.003	0.73 (0.51–1.05)	0.089	0.40 (0.27–0.60)	<0.0001	0.45 (0.30–0.66)	<0.0001
GENDER
Females	0.64 (0.43–0.96)	0.030	0.67 (0.45–1.01)	0.054	0.69 (0.46–1.04)	0.073	0.60 (0.40–0.90)	0.013	0.58 (0.39–0.88)	0.009
Males	0.62 (0.43–0.89)	0.009	0.60 (0.41–0.86)	0.006	0.75 (0.51–1.09)	0.129	0.43 (0.29–0.64)	<0.0001	0.46 (0.32–0.68)	<0.0001
SITES OF ORIGIN
Adrenal gland	0.99 (0.59–1.67)	0.983	0.71 (0.43–1.18)	0.192	0.73 (0.44–1.23)	0.236	0.60 (0.36–1.00)	0.052	0.72 (0.44–1.20)	0.209
Retroperitoneal	0.46 (0.31–0.67)	<0.0001	0.49 (0.34–0.72)	0.0003	0.61 (0.42–0.90)	0.013	0.47 (0.32–0.71)	0.0003	0.41 (0.27–0.62)	<0.0001
Mediastinum	0.67 (0.44–1.01)	0.058	0.89 (0.57–1.37)	0.585	1.01 (0.64–1.58)	0.983	0.50 (0.32–0.79)	0.0027	0.55 (0.36–0.86)	0.009
Others	0.71 (0.29–1.73)	0.444	0.50 (0.20–1.21)	0.123	0.55 (0.22–1.34)	0.185	0.47 (0.18–1.23)	0.124	0.46 (0.18–1.22)	0.120

^aAdjusted for age and gender.

The results were in bold if the 95% CI excluded 1 or P < 0.05.